Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143


Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.

Ferreira CB, Merino-Mansilla A, Llano A, Pérez I, Crespo I, Llinas L, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V.

J Virol. 2013 Nov;87(22):12227-36. doi: 10.1128/JVI.02155-13. Epub 2013 Sep 4.


Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.

Medina-Ramírez M, Sánchez-Merino V, Sánchez-Palomino S, Merino-Mansilla A, Ferreira CB, Pérez I, González N, Alvarez A, Alcocer-González JM, García F, Gatell JM, Alcamí J, Yuste E.

J Virol. 2011 Jun;85(12):5804-13. doi: 10.1128/JVI.02482-10. Epub 2011 Apr 6.


Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.

Hu X, Hong K, Zhao C, Zheng Y, Ma L, Ruan Y, Gao H, Greene K, Sarzotti-Kelsoe M, Montefiori DC, Shao Y.

J Gen Virol. 2012 Oct;93(Pt 10):2267-78. doi: 10.1099/vir.0.043802-0. Epub 2012 Jul 12.


Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.

Sanchez-Merino V, Fabra-Garcia A, Gonzalez N, Nicolas D, Merino-Mansilla A, Manzardo C, Ambrosioni J, Schultz A, Meyerhans A, Mascola JR, Gatell JM, Alcami J, Miro JM, Yuste E.

J Virol. 2016 May 12;90(11):5231-45. doi: 10.1128/JVI.00049-16. Print 2016 Jun 1.


HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity.

Pernas M, Sanchez-Merino V, Casado C, Merino-Mansilla A, Olivares I, Yuste E, Lopez-Galindez C.

PLoS One. 2015 Aug 10;10(8):e0134054. doi: 10.1371/journal.pone.0134054. eCollection 2015.


The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.

Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L; CAPRISA002 Study Team.

J Virol. 2011 May;85(10):4828-40. doi: 10.1128/JVI.00198-11. Epub 2011 Mar 9.


Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Sajadi MM, Lewis GK, Seaman MS, Guan Y, Redfield RR, DeVico AL.

J Virol. 2012 May;86(9):5014-25. doi: 10.1128/JVI.06547-11. Epub 2012 Feb 29.


Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naïve HIV-1-infected children from northern India.

Prakash SS, Andrabi R, Kumar R, Lodha R, Kabra SK, Vajpayee M, Luthra K.

Arch Virol. 2012 Sep;157(9):1797-801. doi: 10.1007/s00705-012-1357-0. Epub 2012 Jun 7.


Epitope specificity of cross-clade neutralizing sera from Chinese HIV-1-positive individuals.

Song H, Chu Y, Zhang H, Wang X, Zhang T, Qiu M, Wu H, Wu Z.

Scand J Immunol. 2013 Oct;78(4):357-70. doi: 10.1111/sji.12091.


Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers.

Palmer CD, Romero-Tejeda M, Scully EP, Lockhart A, Seaman MS, Goldenthal A, Piechocka-Trocha A, Walker BD, Chibnik LB, Jost S, Porichis F.

J Int AIDS Soc. 2016 Dec 9;19(1):21136. doi: 10.7448/IAS.19.1.21136. eCollection 2016.


CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow progressors.

Sapsutthipas S, Tsuchiya N, Pathipavanich P, Ariyoshi K, Sawanpanyalert P, Takeda N, Isarangkura-na-ayuthaya P, Kameoka M.

PLoS One. 2013;8(1):e53920. doi: 10.1371/journal.pone.0053920. Epub 2013 Jan 7.


Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.

van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H.

AIDS. 2009 Nov 27;23(18):2405-14. doi: 10.1097/QAD.0b013e32833243e7.


Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).

Bao MJ, Geng WQ, Cui HL, Zhang XL, Xu DB, Nian H, Dai D, Wang YN, Shang H.

Mol Med Rep. 2012 May;5(5):1311-7. doi: 10.3892/mmr.2012.790. Epub 2012 Feb 14.


Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.

Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, Johnston MN, Gao F, Walker BD, Rosenberg ES.

J Immunol. 2003 Apr 1;170(7):3906-14.


Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L; CAPRISA 002 Study.

J Virol. 2011 Apr;85(7):3128-41. doi: 10.1128/JVI.02658-10. Epub 2011 Jan 26.


Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China.

OuYang Y, Sun J, Huang Y, Lu L, Xu W, Hu X, Hong K, Jiang S, Shao Y, Ma L.

Virol J. 2013 Jan 5;10:10. doi: 10.1186/1743-422X-10-10.


Cross-neutralizing antibody profile of Chinese HIV-1-infected individuals and the viral envelope features from elite neutralizers.

Ren C, Liu S, Li Y, Zhuang M, Yu H, Wang J, Sun F, Li D, Zhang H, Liu W, Liang S, Zhong P, Ling H.

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):472-80. doi: 10.1097/QAI.0000000000000345.


Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India.

Andrabi R, Bala M, Kumar R, Wig N, Hazarika A, Luthra K.

PLoS One. 2012;7(8):e43704. doi: 10.1371/journal.pone.0043704. Epub 2012 Aug 31.

Supplemental Content

Support Center